Rose et al developed nomograms for evaluating women with locally advanced cervical cancer. One nomogram predicts the probability of 2-year progression-free survival (PFS). The authors are from multiple hospitals in the United States and Canada.
Patient selection: woman with locally advanced cervical cancer, age 20 to 85 years, ECOG performance status 0 to 3, tumor size 1 to 30 cm in diameter
Parameters:
(1) histology
(2) race/ethnicity
(3) performance status
(4) tumor size in cm
(5) FIGO stage
(6) grade
(7) pelvic nodes
(8) treatment
|
Tumor Size |
Points |
|---|---|
|
<= 0.5 cm |
0 |
|
0.5 to 4 cm |
(-3.733 * ((diameter)^2)) + (30.39 * (diameter)) - 12.4 |
|
4 to 8 cm |
(-0.3857 * ((diameter)^2)) + (8.929 * (diameter)) + 20.75 |
|
8 to 30 cm |
(-0.03847 * ((diameter)^2)) + (2.89 * (diameter)) + 47.37 |
|
Parameter |
Finding |
Points |
|---|---|---|
|
histology |
squamous |
0 |
|
|
adenocarcinoma |
17.6 |
|
|
adenosquamous |
17.6 |
|
race/ethnicity |
Asian |
0 |
|
|
Hispanic |
3.5 |
|
|
White |
18.1 |
|
|
Black |
30.8 |
|
|
Other |
34 |
|
performance status |
0 |
0 |
|
|
1 |
14.3 |
|
|
2 or 3 |
34.5 |
|
FIGO stage |
IB |
0 |
|
|
IIA |
23.1 |
|
|
IIB |
23.5 |
|
|
IIIA |
89.9 |
|
|
IIIB |
59.4 |
|
|
IVA |
100 |
|
grade |
good (Grade I) |
0 |
|
|
moderate (Grade II) |
8.1 |
|
|
poor (Grade III) |
24.9 |
|
pelvic nodes |
negative |
0 |
|
|
unknown |
0 |
|
|
positive |
28.6 |
|
treatment |
cisplatin plus radiation |
0 |
|
|
other chemotherapy plus radiation |
36 |
total score =
= SUM(points for all 8 parameters)
Interpretation:
• minimum score: 0
• maximum score: 376 (maximum shown on nomogram 350)
• The higher the score the greater the chances of progression-free survival..
|
Score |
Probability of 2-Year PFS |
|---|---|
|
< 34.7 |
> 90% |
|
34.7 to 280 |
(-0.000882* ((points)^2)) - (0.0465 * (points)) + 92.94 |
|
> 280 |
< 15% |
Specialty: Hematology Oncology, Surgery, general, Obstetrics & Gynecology
ICD-10: ,
